Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Down 21.5% in April

Spero Therapeutics, Inc. (NASDAQ:SPRO) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 513,200 shares, a decrease of 21.5% from the March 31st total of 653,800 shares. Based on an average trading volume of 321,500 shares, the short-interest ratio is currently 1.6 days.

Wall Street Analysts Forecast Growth

SPRO has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Thursday, April 4th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Spero Therapeutics in a research note on Monday, March 18th.

Hedge Funds Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Acadian Asset Management LLC increased its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 56.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 272,024 shares of the company’s stock after purchasing an additional 98,485 shares during the period. Acadian Asset Management LLC owned approximately 0.52% of Spero Therapeutics worth $327,000 as of its most recent SEC filing. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Price Performance

SPRO stock traded down $0.02 during midday trading on Tuesday, reaching $1.42. The company had a trading volume of 95,313 shares, compared to its average volume of 288,410. Spero Therapeutics has a 1 year low of $0.99 and a 1 year high of $2.00. The company has a market capitalization of $76.52 million, a P/E ratio of 3.38 and a beta of 0.55. The firm has a 50-day moving average price of $1.63 and a 200-day moving average price of $1.43.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Wednesday, March 13th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $1.14. Spero Therapeutics had a net margin of 21.98% and a return on equity of 38.54%. The business had revenue of $73.52 million during the quarter, compared to analysts’ expectations of $19.40 million. On average, equities analysts predict that Spero Therapeutics will post -0.94 EPS for the current year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.